Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer

Current treatments for castration-resistant prostate cancer (CPRC) that target androgen receptor (AR) signaling improve patient survival, yet ultimately fail. Here we provide novel insights into treatment response for the anti-androgen abiraterone by analyses of a genetically-engineered mouse model...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Zou, Min, Toivanen, Roxanne, Mitrofanova, Antonina, Floch, Nicolas, Hayati, Sheida, Sun, Yanping, Le Magnen, Clémentine, Chester, Daniel, Mostaghel, Elahe A., Califano, Andrea, Rubin, Mark A., Shen, Michael M., Abate-Shen, Cory
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501744/
https://ncbi.nlm.nih.gov/pubmed/28411207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1174
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi